Wakamoto Pharmaceutical Co (TSE:4512) Total Stockholders Equity: 円12,009 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4512 Wakamoto Pharmaceutical Co Ltd TSE:4512
63 GF Score
Price 円290.00
GF Value 円310.35
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Wakamoto Pharmaceutical Co Total Stockholders Equity?

Wakamoto Pharmaceutical Co TSE:4512 63 Total Stockholders Equity is 円12,009 Mil as of Mar. 2026. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円310.35 (Fairly Valued). The stock has 3 warning signs investors should review.

Wakamoto Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2026 was 円12,009 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Wakamoto Pharmaceutical Co's Book Value per Share for the quarter that ended in Mar. 2026 was 円346.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Wakamoto Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.03.

Wakamoto Pharmaceutical Co  (TSE:4512) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Wakamoto Pharmaceutical Co's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(12008.579-0)/34.706
=346.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Wakamoto Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(138.46 + 261.54) / 12008.579
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wakamoto Pharmaceutical Co Total Stockholders Equity Related Terms

Wakamoto Pharmaceutical Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Wakamoto Pharmaceutical Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wakamoto Pharmaceutical Co Total Stockholders Equity Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,480.80 11,906.67 12,026.07 11,610.35 12,008.58

Wakamoto Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,420.33 11,588.30 12,091.07 12,008.58 11,718.87
TSE:4512
63GF Score
Wakamoto Pharmaceutical Co Ltd TSE:4512
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of 円12,009 Mil mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Total Stockholders Equity of 円12,009 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Wakamoto Pharmaceutical Co and its competitors.
Is Wakamoto Pharmaceutical Co's Total Stockholders Equity too high?
Wakamoto Pharmaceutical Co's current Total Stockholders Equity is 円12,009 Mil. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Total Stockholders Equity compare to ZTS?
Wakamoto Pharmaceutical Co's Total Stockholders Equity of 円12,009 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Total Stockholders Equity is 円12,009 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Fairly Valued. The stock's GF Value™ is 円310.35, compared to a current price of 円290.00 — trading 6.6% below its estimated fair value. The current Total Stockholders Equity is 円12,009 Mil. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Total Stockholders Equity is 円12,009 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?

Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued. The current stock price of 円290.00 is trading 6.6% below its estimated GF Value™ of 円310.35. GuruFocus considers Wakamoto Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4512:

  • Total Stockholders Equity: 円12,009 Mil
  • GF Value™: 円310.35 vs. price of 円290.00 (6.6% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wakamoto Pharmaceutical Co Business Description

Address 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score

Get the complete analysis for TSE:4512

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円290.00
Price
円310.35
GF Value